Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy.
Lebow ES, Shaverdian N, Eichholz JE, Kratochvil LB, McCune M, Murciano-Goroff YR, Jee J, Eng J, Chaft JE, Kris MG, Kalashnikova E, Feeney J, Scalise CB, Sudhaman S, Palsuledesai CC, Malhotra M, Krainock M, Sethi H, Aleshin A, Liu MC, Shepherd AF, Wu AJ, Simone CB 2nd, Gelblum DY, Johnson KA, Rudin CM, Gomez DR, Razavi P, Reis-Filho JS, Isbell JM, Li BT, Rimner A. Lebow ES, et al. Among authors: chaft je. Front Oncol. 2023 Sep 19;13:1253629. doi: 10.3389/fonc.2023.1253629. eCollection 2023. Front Oncol. 2023. PMID: 37795442 Free PMC article.
Genetics of vascular anomalies: an update.
Chaft JE, Steckman DA, Blei F. Chaft JE, et al. Lymphat Res Biol. 2003;1(4):283-9. doi: 10.1089/153968503322758085. Lymphat Res Biol. 2003. PMID: 15624556 Review.
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Yasuda H, et al. Among authors: chaft je. Sci Transl Med. 2013 Dec 18;5(216):216ra177. doi: 10.1126/scitranslmed.3007205. Sci Transl Med. 2013. PMID: 24353160 Free PMC article.
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Forde PM, Chaft JE, Pardoll DM. Forde PM, et al. Among authors: chaft je. N Engl J Med. 2018 Aug 30;379(9):e14. doi: 10.1056/NEJMc1808251. N Engl J Med. 2018. PMID: 30157404 No abstract available.
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
Rizvi NA, Rusch V, Pao W, Chaft JE, Ladanyi M, Miller VA, Krug LM, Azzoli CG, Bains M, Downey R, Flores R, Park B, Singh B, Zakowski M, Heelan RT, Shen R, Kris MG. Rizvi NA, et al. Among authors: chaft je. Clin Cancer Res. 2011 May 15;17(10):3500-6. doi: 10.1158/1078-0432.CCR-10-2102. Epub 2011 May 10. Clin Cancer Res. 2011. PMID: 21558399 Free PMC article. Clinical Trial.
Incorporation of crizotinib into the NCCN guidelines.
Riely GJ, Chaft JE, Ladanyi M, Kris MG. Riely GJ, et al. Among authors: chaft je. J Natl Compr Canc Netw. 2011 Dec;9(12):1328-30. doi: 10.6004/jnccn.2011.0113. J Natl Compr Canc Netw. 2011. PMID: 22157552 No abstract available.
152 results